CalciMedica, Inc. entered into a securities purchase agreement for a private placement of 18,673,429 units at a purchase price of approximately $0.80 per unit, expected to raise up to $15 million in gross proceeds and up to $34 million in additional proceeds from warrant exercises. The company plans to use the funds to advance its pulmonary hypertension strategy and fund research and development. CalciMedica, Inc. is a biotechnology company focused on developing CRAC channel inhibitors for various diseases.

CalciMedica, Inc. entered into a First Amendment to Loan Documents with Avenue Venture Opportunities Fund II, L.P. to amend a $10,000,000 loan agreement. The amendment extends the interest-only period to September 30, 2027, and the maturity date to September 1, 2029, while increasing the final payment fee by $200,000. Additionally, the company issued a new warrant to purchase 1,000,000 shares at $1.00 per share and amended an existing warrant to decrease its exercise price from $2.32 to $1.00. CalciMedica, Inc. is a biotechnology company focused on developing therapeutic solutions for inflammatory and regenerative medicine.